Studii clinice pentru BPOC în Oregon
6 studii pentru BPOC caută participanți în Oregon.
Orașe în Oregon
Text oficial al studiului (în engleză)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Medford
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 2 oct. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- The Oregon Clinic - Portland - Northwest 22nd Avenue- Site Number : 8400065, Portland
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 1 oct. 2026 · NCT07190222Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Oregon Health & Science University (OHSU)- Site Number : 8400155, Portland
În curs de recrutareFaza 3
Vârste de la 40 la 80 · Toate sexele · Actualizat 22 sept. 2026 · NCT07190209A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
- WB Contracted Clinical Research Site, Medford
În curs de recrutareFaza 2
Vârste de la 40 la 80 · Toate sexele · Actualizat 15 sept. 2026 · NCT07646587A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Medford
- Research Site, Portland
În curs de recrutareFaza 2
Vârste de 40 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT07082738Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Oregon Health & Science University, Portland
În curs de recrutareStudiu observațional
Vârste de 50 ani și peste · Toate sexele · Actualizat 5 aug. 2025 · NCT06122077Sursă: ClinicalTrials.gov, date preluate la 4 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.